Navigation Links
Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex
Date:3/6/2017

PARSIPPANY, N.J., March 6, 2017 /PRNewswire/ -- Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, today announced that results from a placebo-controlled clinical trial for topical diacerein 1% in the treatment of epidermolysis bullosa simplex (EBS) were presented in a late-breaker session at the American Academy of Dermatology Annual Meeting in Orlando. Results were presented by Professor Johann Bauer, MD, MBA, HCM, head of the University Clinic for Dermatology at the SALK/Paracelsus Medical University and principal investigator in the trial. 

The multicenter, randomized, double-blind, placebo-controlled phase 2 trial included 17 patients with EBS who were treated for four weeks followed by three-month follow-up and subsequent cross-over in year two. Results, which were previously reported, showed a 60 percent reduction in blistering among patients treated with diacerein 1% versus a 15 percent reduction in the placebo group at four weeks. At three months, 67 percent of patients in the placebo group returned to baseline blistering levels, versus 12.5 percent of patients in the diacerein 1% treatment group. Topical diacerein 1% was well tolerated with no treatment-related adverse events reported.

"With no treatment options available, management of EBS remains a significant area of unmet need in healthcare. These results represent a historic advance in research related to EBS indicating the potential to bring patients a safe and effective treatment option in the years ahead," said Dr. Bauer. "Importantly, these results also show the potential for diacerein 1% to offer long-term benefits in patients experiencing blistering associated with EBS."

EBS is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering over their entire bodies. Severe cases of EBS involve widespread blistering that can lead to infections, dehydration, and other medical problems. CCP-020 (diacerein 1% ointment) is an investigational therapy in development at Castle Creek Pharmaceuticals for the treatment of EBS. It is a potentially disease-modifying therapy that blocks an important inflammatory signaling pathway in EBS.

"The results of this important clinical trial for diacerein 1% are another milestone in our plan to identify and advance a pipeline of promising therapies to treat rare and orphan diseases in dermatologic and head/neck indications," said Greg Licholai, MD, president and chief scientific officer at Castle Creek Pharmaceuticals. "We look forward to advancing this development program through the final stages of regulatory review as rapidly as possible in our effort to bring a safe and effective treatment option to patients affected by EBS around the world."

About Castle Creek Pharmaceuticals 
Castle Creek Pharmaceuticals (CCP) is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of rare and debilitating dermatologic and head and neck conditions. For more information, please visit www.castlecreekpharma.com.

Media contact:

Adam Daley 
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/castle-creek-pharmaceuticals-announces-presentation-of-phase-2-clinical-data-for-diacerein-1-ointment-in-treatment-of-epidermolysis-bullosa-simplex-300417864.html


'/>"/>
SOURCE Castle Creek Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder
2. Siltuximab Pivotal Trial Data Show Efficacy for Treatment of Patients with Multicentric Castlemans Disease
3. Maurice Preter, neuropsychiatrist and founder of elite medical concierge, selected Castle Connolly Top Doctor
4. TWi Biotechnology Inc. Announces Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals, LLC
5. Creekridge Capital Adds Revolving Credit Specialist
6. Creekridge Capital Expands Healthcare Sales Team
7. Creekridge Capital Launches Vendor Sales Training Program
8. Creekridge Capital Grows Healthcare Sales Team
9. Creekridge Breaks Monthly and Quarterly Volume Records
10. Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application
11. Creekridge Capital Signs Several New Vendor Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... ... October 11, 2019 , ... Based on data for the first eight ... in deceased organ donors over 2018. Through August 31, 7,786 deceased donors have provided ... national database . At this pace, the Association of Organ Procurement Organizations (AOPO) projects ...
(Date:10/10/2019)... N.Y. (PRWEB) , ... October 10, 2019 , ... ... “In Celebration” Gala Cocktail Reception on Thursday, September 26, at the Westchester Country ... Yubas for the unwavering support of the organization and its mission. , “In ...
(Date:10/8/2019)... ... October 09, 2019 , ... “When Seconds Count: Reports From an Emergency Medical ... the HEMS world through telling the real stories of the EMS flight crew. “When ... author Jay A. Humphrey, an EMS helicopter pilot. He has been a pilot in ...
Breaking Medicine Technology:
(Date:10/15/2019)... ... 2019 , ... Khalieghya Dandie-Evans, a liver transplant recipient from Richmond, Calif. was ... Parade® float in the 131st Rose Parade® on New Year’s Day. She will represent ... Northern Nevada, the organization’s service area. , Khalieghya, 17, grew up believing it was ...
(Date:10/15/2019)... Calif. (PRWEB) , ... October 15, 2019 , ... In ... locations began to shut down in late 2018 . Students who started in ... a time, it seemed as if these students would have to start over. Then ...
(Date:10/11/2019)... , ... October 11, 2019 , ... Only 6% of ... three of them, as well as a female physician leading the sports medicine program. ... today’s girls who want to succeed in traditionally male-oriented fields. , Orthopedic medicine ...
(Date:10/10/2019)... ... October 10, 2019 , ... AltMed Florida , one of ... ), has announced the grand opening of its second MÜV™ Medical Cannabis Dispensary on ... Blvd., Suite 4 in Jacksonville Beach. , Located at Beach Plaza Shopping Center at ...
(Date:10/10/2019)... ... October 10, 2019 , ... In attendance at this ... to hear the significant results of an independent study presented by researchers from ... clinical study poster entitled “The Acute Effects of Citrulline Malate and Bonded Arginine ...
Breaking Medicine News(10 mins):